Community-associated MRSA--resistance and virulence converge.
about
Combating antimicrobial resistance: policy recommendations to save livesCommunity-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infectionsbeta-Neurexin is a ligand for the Staphylococcus aureus MSCRAMM SdrCDevelopment of a vaccine against Staphylococcus aureusA novel gene, fudoh, in the SCCmec region suppresses the colony spreading ability and virulence of Staphylococcus aureusMode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI InhibitorNHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials.Cationic antimicrobial peptide LL-37 is effective against both extra- and intracellular Staphylococcus aureusNovel structurally designed vaccine for S. aureus α-hemolysin: protection against bacteremia and pneumoniaEpidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification.Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains.Contribution of Panton-Valentine leukocidin in community-associated methicillin-resistant Staphylococcus aureus pathogenesis.Comparison of both clinical features and mortality risk associated with bacteremia due to community-acquired methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus.Staphylococcus aureus Panton-Valentine leukocidin contributes to inflammation and muscle tissue injury.Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells.Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice.Highly frequent mutations in negative regulators of multiple virulence genes in group A streptococcal toxic shock syndrome isolates.Looking toward basic science for potential drug discovery targets against community-associated MRSAStructural model of the pre-pore ring-like structure of Panton-Valentine leukocidin: providing dimensionality to biophysical and mutational data.Production of the Bsa lantibiotic by community-acquired Staphylococcus aureus strains.Classification of epidemic community-acquired methicillin-resistant Staphylococcus aureus by anatomical site of isolationMolecular dynamics simulation of the Staphylococcus aureus YsxC protein: molecular insights into ribosome assembly and allosteric inhibition of the protein.Antibiotic resistance genes in the bacteriophage DNA fraction of environmental samples.Patterns of antibacterial use and impact of age, race/ethnicity, and geographic region on antibacterial use in an outpatient medicaid cohortSuccessful multiresistant community-associated methicillin-resistant Staphylococcus aureus lineage from Taipei, Taiwan, that carries either the novel Staphylococcal chromosome cassette mec (SCCmec) type VT or SCCmec type IV.A novel core genome-encoded superantigen contributes to lethality of community-associated MRSA necrotizing pneumonia.Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates.High levels of antibody to panton-valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infectionApplying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.Characterization of SSR42, a novel virulence factor regulatory RNA that contributes to the pathogenesis of a Staphylococcus aureus USA300 representative.Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureusToll-like receptor 2 activation depends on lipopeptide shedding by bacterial surfactants.Discontinued drugs in 2005: anti-infectives.Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infectionGlobal analysis of community-associated methicillin-resistant Staphylococcus aureus exoproteins reveals molecules produced in vitro and during infection.Outbreak in Alberta of community-acquired (USA300) methicillin-resistant Staphylococcus aureus in people with a history of drug use, homelessness or incarcerationPublic health implications of MRSA in Canada.Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
P2860
Q24632857-14D68F43-6DB7-4A99-9DCD-A00FFE54674BQ24652784-AF7FAD79-6E2A-4561-8396-AE9BC1D78A09Q26269932-89A36281-4090-4B65-83B1-2C625C15E677Q27015365-0210A287-7826-4659-AC36-3A7D6D6C7430Q27438134-647CC325-D886-41E5-8F7D-C5D196F35207Q27671875-FB55A230-7644-4120-9F21-232433EC1889Q28298371-7C63BDBB-71C1-4D9F-B6A3-71936D7E05E0Q28393128-EE56116F-7208-48AF-83C2-EED35E632BBEQ28395363-80051304-A48A-47D3-9B34-6D472F11D8E7Q28728777-5F36266E-387E-4DF4-BAC5-BEC8E9D3F0A5Q30367325-3951E560-405A-4320-B807-BEA63DB72685Q30395858-7E7CC8ED-8CF4-49F5-844B-FACA4FADD9B2Q33369089-9BC7AE25-DFE5-41CE-8D52-824D1D868628Q33378604-82101F74-903D-4871-8C00-91C8D50F8ECCQ33487144-471DB01E-A813-4CD4-BADE-D52CBA22B78DQ33510340-5C37D028-E86E-48F2-8DC0-459700599AA6Q33521257-A6F43DAF-9B7F-41ED-BA80-52DE4B8760D9Q33549662-9A9914AD-7868-4B4A-A25C-D90CBC85D3F6Q33560722-7503F903-E7D8-498C-83B0-89BCCB10F789Q33579346-0C87A546-47BD-4841-874C-E8CC08DA154FQ33616955-90BEF33C-F6AF-4DDE-B08D-A76F8AB33CD5Q33634783-141907CC-5EAB-4C27-8F8C-C4D01B4703D7Q33832467-B83BBE13-6742-485D-A424-A0ECACC14FC6Q33842030-4A1DEF10-6FF5-4944-82B6-97670CA31FE5Q33849251-9A7DC205-1F4E-40BC-86A6-7E6F5E8DB81DQ34042156-CE85BE09-20E5-442E-86CA-CC4D8538948EQ34055281-91C6497C-5922-4D98-9519-8029E8E72962Q34123752-913EDD34-73E7-4337-B12B-0AB440173616Q34233286-24A28289-964F-4CF1-8C88-E787A60AE40BQ34250054-3DCB0EDC-F304-4890-9998-1095D6FDEA5EQ34267292-473DB20B-711A-44AD-AA20-DE76A17FBC7BQ34290139-A78944CE-C98F-450C-9A91-D1E2BD24C506Q34309539-9F0FF6DE-AB5F-41AA-9132-ACE1416F0EC7Q34535716-A68EBF3A-441B-4035-A134-19D37B8342FCQ34588892-514AD34A-AD99-48DB-83C7-32DC294AA89BQ34596203-53D352ED-E560-4846-9E5B-679A246E7C44Q34600791-E8B8F175-116B-4ADB-B9F2-E119BB3940D2Q34722480-7B61107F-CB99-44DA-BCEE-C4047128D080Q34722533-12C47969-D439-4D16-BEF0-A76DBEE36543Q34752032-D76EF3D9-AFF9-4225-8167-6A9E9346AC27
P2860
Community-associated MRSA--resistance and virulence converge.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Community-associated MRSA--resistance and virulence converge.
@en
Community-associated MRSA--resistance and virulence converge.
@nl
type
label
Community-associated MRSA--resistance and virulence converge.
@en
Community-associated MRSA--resistance and virulence converge.
@nl
prefLabel
Community-associated MRSA--resistance and virulence converge.
@en
Community-associated MRSA--resistance and virulence converge.
@nl
P356
P1476
Community-associated MRSA--resistance and virulence converge.
@en
P2093
Henry F Chambers
P304
P356
10.1056/NEJME058023
P407
P577
2005-04-01T00:00:00Z